Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.32M | -17.70M | -18.64M | -27.06M | -14.33M |
| Total Depreciation and Amortization | 18.19M | 17.99M | 18.11M | 18.27M | 18.36M |
| Total Amortization of Deferred Charges | 732.00K | 730.00K | 727.00K | 725.00K | 722.00K |
| Total Other Non-Cash Items | 10.27M | 10.74M | 11.64M | 10.26M | 9.39M |
| Change in Net Operating Assets | -4.07M | -2.51M | 2.06M | -28.11M | 3.64M |
| Cash from Operations | 9.80M | 9.25M | 13.89M | -25.92M | 17.78M |
| Capital Expenditure | -11.60M | -10.80M | -13.08M | -5.59M | -7.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.13M | 7.28M | 20.39M | 20.11M | 24.25M |
| Cash from Investing | -5.47M | -3.52M | 7.31M | 14.53M | 17.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -4.00K |
| Issuance of Common Stock | 3.54M | 1.18M | 1.97M | 816.00K | 3.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.86M | -- | -- | -- | -2.05M |
| Cash from Financing | 687.00K | 1.18M | 1.97M | 816.00K | 1.27M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.02M | 6.91M | 23.17M | -10.57M | 36.25M |
